Mirabegron Treatment Guidelines for Overactive Bladder

Efficacy and Clinical Benefits

In older patients with overactive bladder and multiple comorbidities, mirabegron 25 mg has demonstrated safety and therapeutic efficacy, according to the European Urology guidelines 1
Cardiovascular safety analysis has shown no significant concerns with mirabegron treatment, as reported in European Urology 1

The European Association of Urology recommends starting with behavioral interventions, such as bladder training, pelvic floor exercises, and fluid management, as first-line therapy, although this specific recommendation is from Praxis Medical Insights, a similar recommendation can be found in other guidelines 2

Combination therapy with mirabegron 50 mg plus solifenacin 5 mg has demonstrated superior efficacy compared to either monotherapy for reducing urinary incontinence episodes and micturitions, as shown in The Journal of Urology 4
The combination of solifenacin/mirabegron 50 mg was statistically significantly superior to both monotherapies for urgency urinary incontinence episodes, urgency episodes, and nocturia, according to The Journal of Urology 4